Histological findings to five years after early conversion of kidney transplant patients from cyclosporine to everolimus: an analysis from the randomized ZEUS study

Histological findings to five years after early conversion of kidney transplant patients from cyclosporine to everolimus: an analysis from the randomized ZEUS study

Abstract Background Conversion from calcineurin inhibitor (CNI) therapy to everolimus within 6 months after kidney transplantation improves long-term graft function but can increase the risk of mild biopsy-proven acute cellular rejection (BPAR). We performed a post-hoc analysis of histological data...

Full description

Bibliographic Details
Main Authors: Ute Eisenberger, Klemens Budde, Frank Lehner, Claudia Sommerer, Petra Reinke, Oliver Witzke, Rudolf P. Wüthrich, Rolf Stahl, Katharina Heller, Barbara Suwelack, Anja Mühlfeld, Ingeborg A. Hauser, Silvio Nadalin, Martina Porstner, Wolfgang Arns, on behalf of the ZEUS Study Investigators
Format: Article
Language:English
Published: BMC 2018-06-01
Series:BMC Nephrology
Subjects:
Everolimus
mTOR inhibitor
Biopsy
Kidney transplantation
Randomized
Antibody-mediated rejection
Online Access:http://link.springer.com/article/10.1186/s12882-018-0950-1

Internet

http://link.springer.com/article/10.1186/s12882-018-0950-1

Similar Items